Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases

Inclusion Criteria:

1. Patients older than 18 years and younger than 75 years

2. Good general condition: WHO performance status ≤ 2

3. Patients with histological proof of breast, non-small cell lung, or prostate cancerNote: Histological proof can be done on the primitive tumour and/or adenopathyand/or metastatic site.

4. Absence of co-morbidity contra-indicating radio-chemotherapy or surgery

5. Primary tumor accessible to curative-intent treatment (surgery, chemoradiation...)for patients with synchronous metastases

6. Patients with between 1 and 5 synchronous or metachronous bone metastases as definedby NaF-PET or conventional SPECT-CT scan and spinal MRI (if necessary) within 6weeks before randomization)

7. Bones metastases treatable by SBRT

8. Primary cancer considered to be controlled or accessible to curative-intenttreatment (surgery, chemoradiation...) in case of locoregional recurrence formetachronous bone oligo-metastatic disease

9. Women of childbearing potential and male patients must agree to use adequatecontraception for the duration of study participation and up to 3 months followingcompletion of therapy

10. Patients who have received the information sheet, dated and signed the informedconsent form

11. Affiliated to the social security system

Exclusion Criteria:

1. Visceral metastases as defined by FDG-PET (F-Choline-PET or PSMA PET-CT for prostatecancer) and cerebral CT or MRI performed.

2. Previous systemic therapy for metastasis for patients with metachronous metastasis.Prostate and breast cancer patients remain eligible if hormonal treatment wasinitiated 6 months before enrollment

3. All bone metastasis requiring surgical treatment (spinal cord compression,fracture...)

4. More than 5 bone metastases as defined by NaF-PET or conventional SPECT-CT scan andspinal MRI (if spinal bone metastases on NaF-PET)

5. Previous cancer within the 5 years before inclusion (except basal cell carcinoma ofthe skin, in situ carcinoma of the uterine cervix)

6. Previous radiotherapy on bone metastasis (e.g: antalgic radiotherapy)

7. Patient enrolled in another therapeutic trial

8. Pregnant women or breast feeding mothers,

9. Hypersensitivity to the active substance (FDG and NaF or F-Choline or PSMA forprostate cancer) or to any of the excipients

10. Contraindication to MRI (in case of spinal metastases)

11. Patients deprived of liberty or placed under the authority of a tutor. Patients withany psychological, familial, sociological or geographical condition potentiallyhampering compliance with the study protocol and follow-up schedule; thoseconditions should be discussed with the patient before registration in the trial.Patients unable to understand the purpose of the study (language, etc.).